Henlius Delivers On Innovation Agenda In 2021

Revenue At The Chinese Firm Has Increased By 186.3% Year On Year

 
• By Chloe Kent
  
Green ascending arrow
Henlius is expanding beyond biosimilars to develop its own innovative biologic products • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business